Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function. Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnos...
Saved in:
| Published in | Neuro-oncology (Charlottesville, Va.) Vol. 13; no. 6; pp. 591 - 599 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
01.06.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1522-8517 1523-5866 1523-5866 |
| DOI | 10.1093/neuonc/nor042 |
Cover
Loading…
| Abstract | To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function.
Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)-γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis-defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF).
Patients with glioblastoma have increased MDSC counts (CD33+HLADR−) in their blood that are composed of neutrophilic (CD15+; >60%), lineage-negative (CD15−CD14−; 31%), and monocytic (CD14+; 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15-coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma.
The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma. |
|---|---|
| AbstractList | To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function.
Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)-γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis-defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF).
Patients with glioblastoma have increased MDSC counts (CD33+HLADR−) in their blood that are composed of neutrophilic (CD15+; >60%), lineage-negative (CD15−CD14−; 31%), and monocytic (CD14+; 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15-coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma.
The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma. To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function. Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)–γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis–defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF). Patients with glioblastoma have increased MDSC counts (CD33+HLADR−) in their blood that are composed of neutrophilic (CD15 + ; >60%), lineage-negative (CD15 − CD14 − ; 31%), and monocytic (CD14 + ; 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15–coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma. The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma. To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function. Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)-γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis-defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF). Patients with glioblastoma have increased MDSC counts (CD33+HLADR-) in their blood that are composed of neutrophilic (CD15(+); >60%), lineage-negative (CD15(-)CD14(-); 31%), and monocytic (CD14(+); 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15-coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma. The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma. To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function. Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)-γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis-defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF). Patients with glioblastoma have increased MDSC counts (CD33+HLADR-) in their blood that are composed of neutrophilic (CD15(+); >60%), lineage-negative (CD15(-)CD14(-); 31%), and monocytic (CD14(+); 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15-coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma. The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma.To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function. Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)-γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis-defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF). Patients with glioblastoma have increased MDSC counts (CD33+HLADR-) in their blood that are composed of neutrophilic (CD15(+); >60%), lineage-negative (CD15(-)CD14(-); 31%), and monocytic (CD14(+); 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15-coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma. The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma. |
| Author | Raychaudhuri, Baisakhi Borden, Ernest C. Rayman, Patricia Ireland, Joanna Finke, James Rini, Brian Garcia, Jorge Vogelbaum, Michael A. Ko, Jennifer |
| AuthorAffiliation | Brain Tumor and Neuro-Oncology Center , Neurological Institute (B.R., M.A.V.); Department of Immunology , Lerner Research Institute (P.R., J.I., J.F.); Pathology Institute (J.K.); Taussig Cancer Institute (B.R., E.C.B., J.G., J.F.); and Department of Neurosurgery Cleveland Clinic (M.A.V.), Cleveland, Ohio |
| AuthorAffiliation_xml | – name: Brain Tumor and Neuro-Oncology Center , Neurological Institute (B.R., M.A.V.); Department of Immunology , Lerner Research Institute (P.R., J.I., J.F.); Pathology Institute (J.K.); Taussig Cancer Institute (B.R., E.C.B., J.G., J.F.); and Department of Neurosurgery Cleveland Clinic (M.A.V.), Cleveland, Ohio |
| Author_xml | – sequence: 1 givenname: Baisakhi surname: Raychaudhuri fullname: Raychaudhuri, Baisakhi organization: Neurological Institute – sequence: 2 givenname: Patricia surname: Rayman fullname: Rayman, Patricia organization: Neurological Institute – sequence: 3 givenname: Joanna surname: Ireland fullname: Ireland, Joanna organization: Neurological Institute – sequence: 4 givenname: Jennifer surname: Ko fullname: Ko, Jennifer organization: Neurological Institute – sequence: 5 givenname: Brian surname: Rini fullname: Rini, Brian organization: Neurological Institute – sequence: 6 givenname: Ernest C. surname: Borden fullname: Borden, Ernest C. organization: Neurological Institute – sequence: 7 givenname: Jorge surname: Garcia fullname: Garcia, Jorge organization: Neurological Institute – sequence: 8 givenname: Michael A. surname: Vogelbaum fullname: Vogelbaum, Michael A. organization: Neurological Institute – sequence: 9 givenname: James surname: Finke fullname: Finke, James organization: Neurological Institute |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21636707$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUlv1TAUhS1URAdYskXewSath8SON0ioYqhUxAbW1o3jvBo5drDjVu_f4760CJAQK0_fPcc65xQdhRgsQi8pOadE8YtgSwzmIsREWvYEndCO8abrhTg67FnTd1Qeo9OcvxPCaCfoM3TMqOBCEnmCdp_31kc3NqNN7taOOJdlSTbnmLCx3mMwpszFw-piwBBGPJVgDgcX8FKvbVgzvnPrDQ72zu_x6GAXYq5SO-_i4CGvcYbn6OkEPtsXD-sZ-vbh_dfLT831l49Xl--uG9NStTZyZAaI6aurbBkQCkIp2ne8sy1RislBsgm4Vf0g24EKIUCJTnExAJ143_Iz9HbTXcow29HU3yXwekluhrTXEZz-8yW4G72Lt5pTIilhVeD1g0CKP4rNq55dvk8Cgo0l614SpijhqpKvfrf65fEYbgX4BpgUc0520sathyCrs_OaEn1fod4q1FuFdar5a-pR-F_8m42PZfkP-hM0YbHv |
| CitedBy_id | crossref_primary_10_1016_j_canlet_2022_215713 crossref_primary_10_1158_1078_0432_CCR_15_1823 crossref_primary_10_1007_s00262_013_1480_0 crossref_primary_10_1155_2015_717530 crossref_primary_10_1007_s00262_024_03722_5 crossref_primary_10_1002_cam4_421 crossref_primary_10_1038_s41388_017_0024_z crossref_primary_10_1111_eci_12989 crossref_primary_10_1158_0008_5472_CAN_21_3840 crossref_primary_10_1517_14728214_2012_679929 crossref_primary_10_3389_fimmu_2021_770390 crossref_primary_10_1080_08830185_2016_1206097 crossref_primary_10_3390_cells10040893 crossref_primary_10_1089_thy_2015_0289 crossref_primary_10_1172_jci_insight_130748 crossref_primary_10_4049_jimmunol_1401844 crossref_primary_10_1038_onc_2016_273 crossref_primary_10_1007_s11060_015_1720_6 crossref_primary_10_1371_journal_pone_0057114 crossref_primary_10_1016_j_ebiom_2023_104963 crossref_primary_10_1586_14737175_2013_857603 crossref_primary_10_4161_onci_23789 crossref_primary_10_1097_MPH_0000000000001339 crossref_primary_10_1186_s13045_024_01544_7 crossref_primary_10_1016_j_jconrel_2017_08_019 crossref_primary_10_1007_s11060_015_1731_3 crossref_primary_10_1080_2162402X_2018_1507668 crossref_primary_10_1371_journal_pone_0107816 crossref_primary_10_3389_fimmu_2021_809826 crossref_primary_10_1126_sciadv_abh3243 crossref_primary_10_3389_fonc_2021_751183 crossref_primary_10_1007_s13402_019_00447_x crossref_primary_10_1007_s11060_015_1849_3 crossref_primary_10_1007_s11060_020_03483_y crossref_primary_10_1158_1078_0432_CCR_18_2402 crossref_primary_10_1111_imm_12036 crossref_primary_10_1016_j_ymthe_2016_10_003 crossref_primary_10_1186_s40169_018_0211_8 crossref_primary_10_3390_cancers12103039 crossref_primary_10_1007_s11910_014_0440_1 crossref_primary_10_4049_jimmunol_1401144 crossref_primary_10_3389_fgene_2021_750675 crossref_primary_10_3389_fimmu_2024_1326753 crossref_primary_10_1080_10408363_2018_1477729 crossref_primary_10_3390_cancers11030272 crossref_primary_10_1007_s40291_023_00671_0 crossref_primary_10_3389_fonc_2023_1279923 crossref_primary_10_3390_cancers13020210 crossref_primary_10_1007_s11427_019_1735_4 crossref_primary_10_1016_j_wneu_2012_11_059 crossref_primary_10_1523_JNEUROSCI_4668_14_2015 crossref_primary_10_1007_s11060_024_04766_4 crossref_primary_10_1007_s10787_021_00878_9 crossref_primary_10_1177_1753425912463618 crossref_primary_10_1007_s10555_022_10051_5 crossref_primary_10_1515_iss_2019_0001 crossref_primary_10_3389_fimmu_2020_00737 crossref_primary_10_1038_s41388_021_02010_1 crossref_primary_10_1155_2013_835956 crossref_primary_10_1158_2159_8290_CD_19_1355 crossref_primary_10_1016_j_bbi_2015_07_019 crossref_primary_10_1042_AN20110011 crossref_primary_10_1172_JCI68189 crossref_primary_10_1038_s41467_018_08271_x crossref_primary_10_1093_neuonc_noae149 crossref_primary_10_3390_ijms23052509 crossref_primary_10_1016_j_semcancer_2013_02_007 crossref_primary_10_1016_j_addr_2022_114115 crossref_primary_10_1007_s00018_024_05300_5 crossref_primary_10_1007_s00262_014_1639_3 crossref_primary_10_1186_s12885_019_6502_7 crossref_primary_10_1093_neuonc_nox037 crossref_primary_10_1039_D3TB00066D crossref_primary_10_1111_nyas_12469 crossref_primary_10_3389_fimmu_2023_1259797 crossref_primary_10_3390_ijms232415612 crossref_primary_10_4161_onci_21678 crossref_primary_10_1016_j_bbcan_2014_10_003 crossref_primary_10_1016_j_wneu_2013_03_037 crossref_primary_10_1016_j_ymthe_2021_06_023 crossref_primary_10_1016_j_bbadis_2024_167653 crossref_primary_10_1038_s41392_022_01260_z crossref_primary_10_1016_j_canlet_2018_07_034 crossref_primary_10_1080_2162402X_2016_1196311 crossref_primary_10_1093_neuonc_nov107 crossref_primary_10_1158_1078_0432_CCR_12_2130 crossref_primary_10_3389_fimmu_2017_00086 crossref_primary_10_3389_fped_2024_1346493 crossref_primary_10_1016_j_intimp_2019_03_055 crossref_primary_10_1155_2014_326545 crossref_primary_10_1007_s00432_018_02825_8 crossref_primary_10_1093_neuonc_noy072 crossref_primary_10_1186_1746_6148_8_209 crossref_primary_10_1586_era_11_163 crossref_primary_10_1016_j_bbcan_2014_04_003 crossref_primary_10_3390_ijms222413382 crossref_primary_10_1080_2162402X_2016_1163461 crossref_primary_10_2176_nmc_ra2013_0234 crossref_primary_10_3389_fimmu_2020_01402 crossref_primary_10_3389_fcell_2021_717601 crossref_primary_10_18632_oncotarget_12605 crossref_primary_10_3389_fgene_2021_718717 crossref_primary_10_3389_fimmu_2023_1139268 crossref_primary_10_1158_0008_5472_CAN_12_4124 crossref_primary_10_1016_j_prp_2022_153813 crossref_primary_10_1007_s00262_014_1651_7 crossref_primary_10_1073_pnas_1906346116 crossref_primary_10_1016_j_foodres_2023_113770 crossref_primary_10_2217_imt_15_75 crossref_primary_10_3389_fonc_2022_995498 crossref_primary_10_1016_j_clim_2012_06_003 crossref_primary_10_1007_s11060_017_2508_7 crossref_primary_10_1158_1078_0432_CCR_12_1940 crossref_primary_10_1038_nrneurol_2017_64 crossref_primary_10_3389_fimmu_2022_1003651 crossref_primary_10_1038_nri3175 crossref_primary_10_1016_j_neulet_2016_08_002 crossref_primary_10_3389_fonc_2020_01110 crossref_primary_10_1007_s12032_019_1329_2 crossref_primary_10_1080_2162402X_2015_1082027 crossref_primary_10_1038_bjc_2015_238 crossref_primary_10_3109_08820139_2012_695417 crossref_primary_10_3390_cells10010018 crossref_primary_10_1084_jem_20200913 crossref_primary_10_17116_patol201577654_63 crossref_primary_10_1155_2012_764213 crossref_primary_10_1007_s11060_017_2622_6 crossref_primary_10_1097_NEN_0000000000000183 crossref_primary_10_1111_1756_185X_12864 crossref_primary_10_1016_j_intimp_2018_04_013 crossref_primary_10_2217_imt_2017_0122 crossref_primary_10_3389_fimmu_2020_01191 crossref_primary_10_3390_ijms21061954 crossref_primary_10_1016_j_clim_2016_10_008 crossref_primary_10_1002_stem_2393 crossref_primary_10_3390_pharmaceutics16070953 crossref_primary_10_1038_labinvest_2017_19 crossref_primary_10_3389_fonc_2021_665235 crossref_primary_10_1002_2211_5463_13445 crossref_primary_10_3390_cancers14235751 crossref_primary_10_18632_oncotarget_17425 crossref_primary_10_1158_2326_6066_CIR_19_0240 crossref_primary_10_1093_noajnl_vdaa161 crossref_primary_10_1089_jir_2015_0174 crossref_primary_10_3389_fimmu_2021_705580 crossref_primary_10_3389_fonc_2023_1135430 crossref_primary_10_1093_neuonc_nov280 crossref_primary_10_1186_s40478_018_0591_4 crossref_primary_10_1186_s13045_022_01298_0 crossref_primary_10_1172_jci_insight_144619 crossref_primary_10_1007_s11864_024_01211_6 crossref_primary_10_1182_blood_2011_07_365825 crossref_primary_10_1371_journal_pone_0179012 crossref_primary_10_3390_diagnostics12092068 crossref_primary_10_1158_0008_5472_CAN_16_0144 crossref_primary_10_3390_cancers16020308 crossref_primary_10_1093_noajnl_vdab125 crossref_primary_10_1186_2051_1426_2_4 crossref_primary_10_1371_journal_pone_0096318 crossref_primary_10_1093_neuonc_nov157 crossref_primary_10_1093_neuonc_now002 crossref_primary_10_3389_fonc_2021_770561 crossref_primary_10_1080_2162402X_2015_1083669 crossref_primary_10_3390_cells10071783 crossref_primary_10_1080_2162402X_2021_1957215 crossref_primary_10_1360_SSV_2024_0280 crossref_primary_10_1186_s41983_023_00635_5 crossref_primary_10_3390_ijms23116312 crossref_primary_10_1038_s41388_022_02312_y crossref_primary_10_3389_fonc_2017_00143 crossref_primary_10_1111_imr_12444 crossref_primary_10_1016_j_smim_2016_03_018 crossref_primary_10_3390_ijms21103704 crossref_primary_10_3389_fimmu_2020_582106 crossref_primary_10_3390_cancers14164023 crossref_primary_10_4049_jimmunol_1300654 crossref_primary_10_1007_s10637_017_0449_9 crossref_primary_10_1093_intimm_dxv053 crossref_primary_10_1186_2047_1440_1_15 crossref_primary_10_1007_s00262_019_02302_2 crossref_primary_10_3389_fimmu_2018_00946 crossref_primary_10_1002_cam4_5681 crossref_primary_10_3389_fmedt_2021_791596 crossref_primary_10_1038_s41568_021_00347_z crossref_primary_10_1186_s40425_016_0112_6 crossref_primary_10_1007_s00109_019_01835_4 crossref_primary_10_1093_noajnl_vdad088 crossref_primary_10_3389_fimmu_2022_974996 crossref_primary_10_1007_s10571_017_0536_7 crossref_primary_10_1021_acs_chemrev_3c00062 crossref_primary_10_1007_s00262_012_1294_5 crossref_primary_10_1186_s40164_024_00505_7 crossref_primary_10_3389_fimmu_2020_02100 crossref_primary_10_3390_ijms222212608 crossref_primary_10_1136_jitc_2022_004805 crossref_primary_10_1016_j_ijpt_2024_100633 crossref_primary_10_1158_1078_0432_CCR_17_2617 crossref_primary_10_1126_scitranslmed_abn6758 crossref_primary_10_2217_imt_14_35 crossref_primary_10_1093_neuonc_now034 crossref_primary_10_1371_journal_pone_0134425 crossref_primary_10_3109_08820139_2012_689591 crossref_primary_10_1016_j_bioactmat_2023_08_022 crossref_primary_10_1182_blood_2016_04_713206 crossref_primary_10_1038_icb_2016_11 crossref_primary_10_1016_j_humimm_2013_09_011 crossref_primary_10_1002_cam4_239 crossref_primary_10_1016_j_trecan_2022_04_010 crossref_primary_10_1080_14737140_2016_1192470 crossref_primary_10_3390_jcm12144780 crossref_primary_10_2147_OTT_S486411 crossref_primary_10_3390_cancers5041379 crossref_primary_10_1007_s11060_016_2270_2 crossref_primary_10_1007_s00262_019_02317_9 crossref_primary_10_3389_fonc_2022_1005069 crossref_primary_10_1016_j_intimp_2024_112949 crossref_primary_10_1182_blood_2012_08_449413 crossref_primary_10_1136_jitc_2019_000207 crossref_primary_10_3389_fmed_2023_1175507 crossref_primary_10_1038_s41392_024_01765_9 crossref_primary_10_1073_pnas_1910856117 crossref_primary_10_1016_j_wneu_2018_04_020 crossref_primary_10_3389_fimmu_2022_927233 crossref_primary_10_1007_s00262_019_02332_w crossref_primary_10_1158_1078_0432_CCR_12_3725 crossref_primary_10_1155_2020_8844313 crossref_primary_10_1002_INMD_20240070 crossref_primary_10_1158_1078_0432_CCR_14_0514 crossref_primary_10_1007_s11940_018_0499_0 crossref_primary_10_1007_s00262_018_2214_0 crossref_primary_10_1016_j_pharmthera_2020_107790 crossref_primary_10_1002_ijc_32102 crossref_primary_10_1189_jlb_1012531 crossref_primary_10_1038_srep31397 crossref_primary_10_1371_journal_pone_0055818 crossref_primary_10_1080_14728214_2016_1186643 crossref_primary_10_1158_2326_6066_CIR_13_0028 crossref_primary_10_1172_jci_insight_85841 crossref_primary_10_1186_s40478_021_01156_z crossref_primary_10_4049_jimmunol_1501853 crossref_primary_10_1016_S1499_3872_15_60413_1 crossref_primary_10_3389_fimmu_2021_746621 crossref_primary_10_4161_onci_21747 crossref_primary_10_1016_j_wneu_2013_01_074 crossref_primary_10_1080_2162402X_2015_1047581 crossref_primary_10_1172_jci_insight_122264 crossref_primary_10_1371_journal_pone_0126022 crossref_primary_10_1155_2016_7487313 crossref_primary_10_1016_j_jaci_2014_08_040 crossref_primary_10_1080_2162402X_2024_2423983 crossref_primary_10_18632_oncotarget_16386 crossref_primary_10_1016_j_cyto_2024_156759 crossref_primary_10_3389_fimmu_2021_637146 |
| Cites_doi | 10.1002/eji.200939903 10.1111/j.1600-065X.2008.00608.x 10.1245/s10434-009-0809-6 10.1158/1078-0432.CCR-08-1332 10.1007/s00432-009-0634-0 10.1158/0008-5472.CAN-08-4709 10.1002/pros.21078 10.1200/JCO.2006.08.5829 10.1158/0008-5472.CAN-04-4505 10.1038/nri2506 10.1007/s00595-002-2563-2 10.1158/0008-5472.CAN-09-3278 10.4049/jimmunol.166.1.678 10.1182/blood.V84.6.1737.1737 10.1084/jem.20061104 10.1093/neuonc/nop023 10.1073/pnas.0902280106 10.1097/00002371-200111000-00001 10.1111/j.1600-065X.2008.00602.x 10.1158/0008-5472.CAN-08-1921 10.1158/1078-0432.CCR-07-0182 10.1097/CEJ.0b013e32832405eb 10.1016/0268-960X(92)90007-D 10.1016/j.nec.2009.08.005 10.1016/j.coi.2010.01.021 10.1158/1078-0432.CCR-08-0165 10.1146/annurev.nutr.22.110801.140547 10.1016/S0009-8981(00)00432-0 10.4049/jimmunol.171.3.1232 10.1016/j.coph.2009.06.014 10.1158/0008-5472.CAN-09-3767 10.1212/WNL.54.1.259 10.1007/s00262-010-0855-8 10.1007/978-0-387-72005-0_22 10.1111/j.1476-5381.2009.00291.x |
| ContentType | Journal Article |
| Copyright | The Author(s) 2011. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2011 |
| Copyright_xml | – notice: The Author(s) 2011. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2011 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1093/neuonc/nor042 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1523-5866 |
| EndPage | 599 |
| ExternalDocumentID | PMC3107102 21636707 10_1093_neuonc_nor042 10.1093/neuonc/nor042 |
| Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01CA116255 – fundername: NCI NIH HHS grantid: R01 CA150959 |
| GroupedDBID | --- .2P .I3 .XZ .ZR 0R~ 123 18M 1TH 29N 2WC 36B 4.4 48X 53G 5VS 5WD 70D AABZA AACZT AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQNK ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMB EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HYE HZ~ IOX J21 KBUDW KOP KQ8 KSI KSN M49 MHKGH N9A NGC NOMLY NOYVH NU- O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM Q1. Q5Y RD5 RHF ROX RPM RUSNO RW1 RXO SV3 TEORI TJX TR2 UDS W8F WOQ X7H YAYTL YKOAZ YXANX ~91 AAYXX ABDFA ABEJV ABGNP ABPQP ABVGC ADNBA AEMQT AGORE AHMMS AJBYB AJNCP ALXQX CITATION JXSIZ AHGBF CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c419t-7d2ca0c8acc742a01a69918535e409927b72fa3e98b74b1666a965936ba1f3843 |
| ISSN | 1522-8517 1523-5866 |
| IngestDate | Thu Aug 21 14:11:10 EDT 2025 Fri Jul 11 12:43:02 EDT 2025 Mon Jul 21 05:28:00 EDT 2025 Tue Jul 01 00:42:09 EDT 2025 Thu Apr 24 23:05:40 EDT 2025 Wed Aug 28 03:23:59 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Arginase GBM MDSC G-CSF neutrophil |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c419t-7d2ca0c8acc742a01a69918535e409927b72fa3e98b74b1666a965936ba1f3843 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://academic.oup.com/neuro-oncology/article-pdf/13/6/591/6207023/nor042.pdf |
| PMID | 21636707 |
| PQID | 870291039 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3107102 proquest_miscellaneous_870291039 pubmed_primary_21636707 crossref_citationtrail_10_1093_neuonc_nor042 crossref_primary_10_1093_neuonc_nor042 oup_primary_10_1093_neuonc_nor042 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-06-01 |
| PublicationDateYYYYMMDD | 2011-06-01 |
| PublicationDate_xml | – month: 06 year: 2011 text: 2011-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Neuro-oncology (Charlottesville, Va.) |
| PublicationTitleAlternate | Neuro Oncol |
| PublicationYear | 2011 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | (16_33913056) 2009; 69 Waziri (11_36086453) 2010; 21 (25_37116004) 2010; 70 (7_34238021) 2009; 15 Munder (26_35631778) 2009; 158 Hintzen (34_6433907) 2000; 54 (22_22950575) 2006; 203 Lieschke (32_21322544) 1994; 84 (27_17091517) 2002 Zea (15_18807237) 2005; 65 Marigo (35_30714325) 2008; 222 Shukla (29_34312435) 2009; 18 (3_36661041) 2001; 24 Liu (17_35232011) 2010; 136 Dolcetti (24_36077646) 2010; 40 Almand (5_11008297) 2001; 166 Kaufman (18_36003947) 2010; 17 Gabrilovich (2_33956224) 2009; 9 Rapoport (31_9835425) 1992; 6 (23_36221655) 2010; 12 Ostrand-Rosenberg (1_37164821) 2010; 59 Rodriguez (14_17731484) 2003; 171 Ugel (4_35309468) 2009; 9 Nagaraj (10_29285150) 2007; 601 (19_37287728) 2010; 70 Filipazzi (20_28851063) 2007; 25 Rodriguez (9_30714326) 2008; 222 Polat (28_17775813) 2003; 33 Vuk-Pavlovic (21_35969562) 2010; 70 (8_34239570) 2009; 69 Kusmartsev (13_32860681) 2008; 14 (33_34512455) 2009; 106 Porembska (30_11070841) 2001; 305 Peranzoni (12_36707838) 2010; 22 Talmadge (6_29411549) 2007; 13 1375123 - Blood Rev. 1992 Mar;6(1):43-57 19764983 - Br J Pharmacol. 2009 Oct;158(3):638-51 19282757 - Eur J Cancer Prev. 2009 Jun;18(3):199-202 12055339 - Annu Rev Nutr. 2002;22:87-105 19616475 - Curr Opin Pharmacol. 2009 Aug;9(4):470-81 18364001 - Immunol Rev. 2008 Apr;222:162-79 17101732 - J Exp Med. 2006 Nov 27;203(12):2691-702 12874210 - J Immunol. 2003 Aug 1;171(3):1232-9 19201693 - Cancer Res. 2009 Feb 15;69(4):1553-60 19915919 - Ann Surg Oncol. 2010 Mar;17(3):718-30 11123353 - J Immunol. 2001 Jan 1;166(1):678-89 18364002 - Immunol Rev. 2008 Apr;222:180-91 19902470 - Prostate. 2010 Mar 1;70(4):443-55 11759067 - J Immunother. 2001 Nov-Dec;24(6):431-46 17875751 - Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5243-8 20308313 - Neuro Oncol. 2010 Apr;12(4):351-65 19944964 - Neurosurg Clin N Am. 2010 Jan;21(1):31-42 19088044 - Clin Cancer Res. 2008 Dec 15;14(24):8270-8 20414655 - Cancer Immunol Immunother. 2010 Oct;59(10):1593-600 19197294 - Nat Rev Immunol. 2009 Mar;9(3):162-74 19941314 - Eur J Immunol. 2010 Jan;40(1):22-35 17577033 - J Clin Oncol. 2007 Jun 20;25(18):2546-53 19572148 - J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 19346489 - Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7 20171075 - Curr Opin Immunol. 2010 Apr;22(2):238-44 17713008 - Adv Exp Med Biol. 2007;601:213-23 12928840 - Surg Today. 2003;33(9):655-61 20406969 - Cancer Res. 2010 May 1;70(9):3526-36 19276342 - Cancer Res. 2009 Mar 15;69(6):2514-22 20484028 - Cancer Res. 2010 Jun 1;70(11):4335-45 15833831 - Cancer Res. 2005 Apr 15;65(8):3044-8 7521686 - Blood. 1994 Sep 15;84(6):1737-46 19276286 - Clin Cancer Res. 2009 Mar 15;15(6):2148-57 11249934 - Clin Chim Acta. 2001 Mar;305(1-2):157-65 10636166 - Neurology. 2000 Jan 11;54(1):259-61 |
| References_xml | – volume: 40 start-page: 22 issn: 0014-2980 issue: 1 year: 2010 ident: 24_36077646 publication-title: European journal of immunology doi: 10.1002/eji.200939903 – volume: 222 start-page: 180 issn: 0105-2896 year: 2008 ident: 9_30714326 publication-title: Immunological reviews doi: 10.1111/j.1600-065X.2008.00608.x – volume: 17 start-page: 718 issn: 1068-9265 issue: 3 year: 2010 ident: 18_36003947 publication-title: Annals of Surgical Oncology doi: 10.1245/s10434-009-0809-6 – volume: 15 start-page: 2148 issn: 1078-0432 issue: 6 year: 2009 ident: 7_34238021 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-08-1332 – volume: 136 start-page: 35 issn: 0171-5216 issue: 1 year: 2010 ident: 17_35232011 publication-title: Journal of cancer research and clinical oncology doi: 10.1007/s00432-009-0634-0 – volume: 69 start-page: 2514 issn: 0008-5472 issue: 6 year: 2009 ident: 8_34239570 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-08-4709 – volume: 70 start-page: 443 issn: 0270-4137 issue: 4 year: 2010 ident: 21_35969562 publication-title: The Prostate doi: 10.1002/pros.21078 – volume: 25 start-page: 2546 issn: 0732-183X issue: 18 year: 2007 ident: 20_28851063 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2006.08.5829 – volume: 65 start-page: 3044 issn: 0008-5472 issue: 8 year: 2005 ident: 15_18807237 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-04-4505 – volume: 9 start-page: 162 issn: 1474-1733 issue: 3 year: 2009 ident: 2_33956224 publication-title: Nature reviews. Immunology doi: 10.1038/nri2506 – volume: 33 start-page: 655 issn: 0941-1291 issue: 9 year: 2003 ident: 28_17775813 publication-title: Surgery today doi: 10.1007/s00595-002-2563-2 – volume: 70 start-page: 3526 issn: 0008-5472 issue: 9 year: 2010 ident: 25_37116004 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-09-3278 – volume: 166 start-page: 678 issn: 0022-1767 issue: 1 year: 2001 ident: 5_11008297 publication-title: The Journal of Immunology doi: 10.4049/jimmunol.166.1.678 – volume: 84 start-page: 1737 issn: 0006-4971 issue: 6 year: 1994 ident: 32_21322544 publication-title: Blood doi: 10.1182/blood.V84.6.1737.1737 – volume: 203 start-page: 2691 issn: 0022-1007 issue: 12 year: 2006 ident: 22_22950575 publication-title: Journal of Experimental Medicine doi: 10.1084/jem.20061104 – volume: 12 start-page: 351 issn: 1522-8517 issue: 4 year: 2010 ident: 23_36221655 publication-title: Neuro-Oncology doi: 10.1093/neuonc/nop023 – volume: 106 start-page: 6742 issn: 0027-8424 issue: 16 year: 2009 ident: 33_34512455 publication-title: PNAS doi: 10.1073/pnas.0902280106 – volume: 24 start-page: 431 issn: 1524-9557 year: 2001 ident: 3_36661041 doi: 10.1097/00002371-200111000-00001 – volume: 222 start-page: 162 issn: 0105-2896 year: 2008 ident: 35_30714325 publication-title: Immunological reviews doi: 10.1111/j.1600-065X.2008.00602.x – volume: 69 start-page: 1553 issn: 0008-5472 issue: 4 year: 2009 ident: 16_33913056 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-08-1921 – volume: 13 start-page: 5243 issn: 1078-0432 issue: 18 year: 2007 ident: 6_29411549 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-07-0182 – volume: 18 start-page: 199 issn: 0959-8278 issue: 3 year: 2009 ident: 29_34312435 publication-title: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) doi: 10.1097/CEJ.0b013e32832405eb – volume: 6 start-page: 43 issn: 0268-960X issue: 1 year: 1992 ident: 31_9835425 publication-title: Blood reviews doi: 10.1016/0268-960X(92)90007-D – volume: 21 start-page: 31 issn: 1042-3680 issue: 1 year: 2010 ident: 11_36086453 publication-title: Neurosurgery clinics of North America doi: 10.1016/j.nec.2009.08.005 – volume: 22 start-page: 238 issn: 0952-7915 issue: 2 year: 2010 ident: 12_36707838 publication-title: Current opinion in immunology doi: 10.1016/j.coi.2010.01.021 – volume: 14 start-page: 8270 issn: 1078-0432 issue: 24 year: 2008 ident: 13_32860681 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-08-0165 – issn: 0199-9885 year: 2002 ident: 27_17091517 publication-title: Annual review of nutrition doi: 10.1146/annurev.nutr.22.110801.140547 – volume: 305 start-page: 157 issn: 1873-3492 issue: 1-2 year: 2001 ident: 30_11070841 publication-title: Clinica Chimica Acta doi: 10.1016/S0009-8981(00)00432-0 – volume: 171 start-page: 1232 issn: 0022-1767 issue: 3 year: 2003 ident: 14_17731484 publication-title: The Journal of Immunology doi: 10.4049/jimmunol.171.3.1232 – volume: 9 start-page: 470 issn: 1471-4892 issue: 4 year: 2009 ident: 4_35309468 publication-title: Current opinion in pharmacology doi: 10.1016/j.coph.2009.06.014 – volume: 70 start-page: 4335 issn: 0008-5472 issue: 11 year: 2010 ident: 19_37287728 publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-09-3767 – volume: 54 start-page: 259 issn: 0028-3878 issue: 1 year: 2000 ident: 34_6433907 publication-title: Neurology doi: 10.1212/WNL.54.1.259 – volume: 59 start-page: 1593 issn: 0340-7004 issue: 10 year: 2010 ident: 1_37164821 publication-title: Cancer immunology, immunotherapy : CII doi: 10.1007/s00262-010-0855-8 – volume: 601 start-page: 213 issn: 0065-2598 year: 2007 ident: 10_29285150 publication-title: Advances in experimental medicine and biology doi: 10.1007/978-0-387-72005-0_22 – volume: 158 start-page: 638 issn: 0007-1188 issue: 3 year: 2009 ident: 26_35631778 publication-title: British journal of pharmacology doi: 10.1111/j.1476-5381.2009.00291.x – reference: 11249934 - Clin Chim Acta. 2001 Mar;305(1-2):157-65 – reference: 18364002 - Immunol Rev. 2008 Apr;222:180-91 – reference: 18364001 - Immunol Rev. 2008 Apr;222:162-79 – reference: 11123353 - J Immunol. 2001 Jan 1;166(1):678-89 – reference: 19346489 - Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7 – reference: 20414655 - Cancer Immunol Immunother. 2010 Oct;59(10):1593-600 – reference: 19915919 - Ann Surg Oncol. 2010 Mar;17(3):718-30 – reference: 20308313 - Neuro Oncol. 2010 Apr;12(4):351-65 – reference: 12874210 - J Immunol. 2003 Aug 1;171(3):1232-9 – reference: 10636166 - Neurology. 2000 Jan 11;54(1):259-61 – reference: 19944964 - Neurosurg Clin N Am. 2010 Jan;21(1):31-42 – reference: 20171075 - Curr Opin Immunol. 2010 Apr;22(2):238-44 – reference: 17713008 - Adv Exp Med Biol. 2007;601:213-23 – reference: 20406969 - Cancer Res. 2010 May 1;70(9):3526-36 – reference: 17875751 - Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5243-8 – reference: 7521686 - Blood. 1994 Sep 15;84(6):1737-46 – reference: 17101732 - J Exp Med. 2006 Nov 27;203(12):2691-702 – reference: 19276342 - Cancer Res. 2009 Mar 15;69(6):2514-22 – reference: 12928840 - Surg Today. 2003;33(9):655-61 – reference: 20484028 - Cancer Res. 2010 Jun 1;70(11):4335-45 – reference: 19616475 - Curr Opin Pharmacol. 2009 Aug;9(4):470-81 – reference: 17577033 - J Clin Oncol. 2007 Jun 20;25(18):2546-53 – reference: 19764983 - Br J Pharmacol. 2009 Oct;158(3):638-51 – reference: 19941314 - Eur J Immunol. 2010 Jan;40(1):22-35 – reference: 19197294 - Nat Rev Immunol. 2009 Mar;9(3):162-74 – reference: 19201693 - Cancer Res. 2009 Feb 15;69(4):1553-60 – reference: 19088044 - Clin Cancer Res. 2008 Dec 15;14(24):8270-8 – reference: 11759067 - J Immunother. 2001 Nov-Dec;24(6):431-46 – reference: 19276286 - Clin Cancer Res. 2009 Mar 15;15(6):2148-57 – reference: 1375123 - Blood Rev. 1992 Mar;6(1):43-57 – reference: 19282757 - Eur J Cancer Prev. 2009 Jun;18(3):199-202 – reference: 19902470 - Prostate. 2010 Mar 1;70(4):443-55 – reference: 19572148 - J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 – reference: 12055339 - Annu Rev Nutr. 2002;22:87-105 – reference: 15833831 - Cancer Res. 2005 Apr 15;65(8):3044-8 |
| SSID | ssj0021561 |
| Score | 2.4659882 |
| Snippet | To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and... |
| SourceID | pubmedcentral proquest pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 591 |
| SubjectTerms | Arginase - metabolism Basic and Translational Investigations Brain Neoplasms - blood Brain Neoplasms - diagnosis Brain Neoplasms - immunology Case-Control Studies Cells, Cultured Enzyme-Linked Immunosorbent Assay Flow Cytometry Glioblastoma - blood Glioblastoma - diagnosis Glioblastoma - immunology Granulocyte Colony-Stimulating Factor - metabolism Humans Interferon-gamma - metabolism Leukocytes, Mononuclear - immunology Lymphocyte Activation Middle Aged Myeloid Cells - immunology Myeloid Cells - pathology T-Lymphocytes - immunology |
| Title | Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21636707 https://www.proquest.com/docview/870291039 https://pubmed.ncbi.nlm.nih.gov/PMC3107102 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuiDfbAjIS4lLSJs7DyREQqBSVA2ql3iLbcbopi13tJpXKf-O_MY6d1LtQKFyiyPY6Wc-X8cx4Hgi9lJVgNa_rQEj4mpI6KYKcURJUlApOasYJ6x1kP2d7R8n-cXo8mfzwvJa6lu-I77-NK_kfqkIb0NVEyf4DZcdJoQHugb5wBQrD9Vo0PriQc91UQQUPOwfJcdmd9X6terFtDPLbTIjum6vP1Z8SmF1s8G50GVVdeBtI1_MLY4k1jncw1cm80Rwk61Y7xn06pHnqFjrQStjcTeYM2BzY6xZE1nMTV9g7zrIdz8LwhQGPZV0162xU-1vWLNnXWeP1OzOsrRfQjDvFRxNpYy3f-5opNXZ80r5njm-5iDwPqz9FRPrMGBRlkAjthiyHtjhIc1upZeTgsYdUnx2nthKY29lTW4rpl03DJtRSsoPFMzd6EdqMX2uZuK8cewPdJKClkMFY5PR9UI1tul73N1yKV5hi106wa3--IhKthFl62s66064nBR3eRXec-oLfWCzeQxOp7qNbB85B4wE6WYMkvoQkNpDEPiQx0BYPkMSNwgMksYEk7iGJR0hiH5IP0dGH94fv9gJXyyMQSVS0Aa2IYKHI4Sk0ISyMWAaaCciKqUxASSGUU-AMsSxyThNuzrKZSXUZZ5xFdZwn8SO0obSSTxDOY5ryCqY1sU0VyTgNC8FrUIzjtM6qaIpeD8tZCpfo3tRbmZfW4SIu7eqXdvWn6NU4_MxmeLlq4Augzd_G4IFyJfBps7BMSd0tS9gXSWH8LqbosSXkOBMBnSijIZ0iukLicYBJAb_ao5pZnwoelDOjImxe49W20O3Lj_Ap2mgXnXwGAnXLn_ew_QnnDNlF |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Myeloid-derived+suppressor+cell+accumulation+and+function+in+patients+with+newly+diagnosed+glioblastoma&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Raychaudhuri%2C+Baisakhi&rft.au=Rayman%2C+Patricia&rft.au=Ireland%2C+Joanna&rft.au=Ko%2C+Jennifer&rft.date=2011-06-01&rft.pub=Oxford+University+Press&rft.issn=1522-8517&rft.eissn=1523-5866&rft.volume=13&rft.issue=6&rft.spage=591&rft.epage=599&rft_id=info:doi/10.1093%2Fneuonc%2Fnor042&rft.externalDocID=10.1093%2Fneuonc%2Fnor042 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon |